RELATED STUDY

In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects

Key Findings:  The selective MAGL inhibitor, KML29, significantly reduced inflammation and swelling in this mouse model of neuropathic and inflammatory pain and protected gastric tissue. It did not appear to have any unpleasant cannabimimetic side effects and may present a therapeutic adjunct target to neuropathic pain management without the risks presented by NSAIDS.

Type of Study:  Animal Study

Study Result:  Positive

Study Location(s):  United States

Year of Pub:  2014


Cannabinoids Studied:  Tetrahydrocannabinol (THC), AM-x Synthetic Cannabinoids, SR-x Synthetic Cannabinoids, Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Monoacylglycerol Lipase (MAGL), Synthetic Cannabinoid (unspecified), Palmitoylethanolamide (PEA)

Phytocannabinoid Source:  Not Applicable

Receptors Studied:  CB1, CB2, CB1 agonist, CB1 antagonist, CB2 antagonist

Route of Administration:  Injection



Link to study